Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Agenus Inc. CEO Garo H. Armen received 32,697 shares of common stock in lieu of cash salary for the pay period ending April 5, 2024, while also disposing of 1,335,325 shares.

Summary

• Garo H. Armen, CEO of Agenus Inc., received 32,697 shares of Agenus common stock on April 5, 2024, as payment in lieu of cash salary.
• The stock was issued under the Agenus Inc. 2019 Equity Incentive Plan and was fully vested upon issuance.
• The price of the stock was $0.50 per share, which was the closing price on April 5, 2024.
• Armen also disposed of 1,335,325 shares of common stock.
• Following the transaction, Armen directly owns 32,697 shares.
• Armen indirectly owns 625,969 shares through IRA accounts and 579,000 shares as trustee and investment authority for the Garo Armen 2020 2 Year AG GRAT and as a general partner in Pixie Partners.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the CEO taking stock instead of salary could be seen as positive, the disposal of a large number of shares introduces uncertainty. The low stock price is also a concern.

Positives

• The CEO's willingness to accept stock in lieu of cash salary may signal confidence in the company's future prospects.
• The shares are fully vested upon issuance, aligning the CEO's interests with those of the shareholders.

Negatives

• The disposal of 1,335,325 shares by the CEO could be interpreted negatively by the market, although the reason for the disposal is not specified in this document.
• The low stock price of $0.50 may be a concern for investors.

Risks

• The document does not provide enough information to assess the reasons behind the disposal of shares, which could be a risk factor.
• The reliance on stock-based compensation may dilute existing shareholders if not managed carefully.

Industry Context

This type of filing is standard for corporate insiders and provides transparency into their transactions in the company's stock. It's common for executives to receive stock options or grants as part of their compensation packages, and their trading activity is closely watched by investors.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry, particularly for companies that are still in the development stage.
• Comparing Agenus's stock-based compensation practices to those of its peers, such as BioNTech or Moderna, would provide a better understanding of whether the company's approach is in line with industry standards.
• Executive compensation packages often include a mix of salary, stock options, and performance-based bonuses, and the specific mix can vary depending on the company's size, stage of development, and financial performance.

Stakeholder Impact

• Shareholders may be concerned about the disposal of shares by the CEO.
• Employees may view the CEO's acceptance of stock in lieu of cash salary as a positive sign of commitment to the company.

Key Dates